Sai Parenteral's IPO Details
MAINBOARD
Sai Parenteral's IPO DRHP (Draft Red Herring Prospectus) has been SEBI Approval Received.
Offer for Sale consists of 35,00,000 shares (aggregating up to ₹0.00 Cr.).
The Lead Managers for Sai Parenteral's IPO are crucial for the offering's success. They are responsible for a wide range of tasks, including preparing the company for the public market, managing the regulatory filings, and marketing the IPO to potential investors. The lead manager for this offering is Arihant Capital Markets Ltd. To assess their past performance and success in previous IPOs, you can view the Lead Manager Performance Summary report.
For detailed information, Refer to the Sai Parenteral's Limited DRHP.
Sai Parenteral's IPO Details
Sai Parenteral's IPO Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
To be announced | |||
Sai Parenteral's IPO Reservation
Promoter Holding
Documents
Sai Parenteral's IPO Valuations
Sai Parenteral's Financial Information
| Period Ended | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
| Assets | 272.39 | 268.10 | 133.96 |
| Total Income | 163.74 | 155.18 | 97.03 |
| Profit After Tax | 14.43 | 8.42 | 4.38 |
| EBITDA | 39.44 | 31.70 | 17.64 |
| NET Worth | 95.78 | 76.40 | 31.49 |
| Reserves and Surplus | 80.36 | 61.30 | 24.34 |
| Total Borrowing | 93.95 | 118.79 | 68.55 |
| Amount in ₹ Crore | |||
About Sai Parenteral's IPO
Incorporated in 2001, Sai Parenteral's Ltd. is a diversified pharmaceutical formulations company with expertise in research, development, and manufacturing.
The company operates in two segments: Branded Generic Formulations and Contract Development and Manufacturing Organisation (CDMO) products and services for domestic and international markets.
The product portfolio spans multiple therapeutic areas including cardiovascular, neuropsychiatry, anti-diabetic, respiratory health, antibiotics, gastroenterology, vitamins, minerals and supplements (VMS), analgesics, and dermatology. Offerings are across dosage forms such as injectables, tablets, capsules, liquid orals, and ointments.
Sai Parenteral's serves a wide customer base comprising central and state government agencies, pharmaceutical companies, public and private hospitals, and super stockists in India. The company entered exports in FY 2023 after acquiring two internationally accredited facilities in Hyderabad, Telangana, and now supplies to regulated and semi-regulated markets in Australia, New Zealand, Southeast Asia, the Middle East, and Africa.
The company owns and operates five manufacturing facilities in India. Four are located in Hyderabad, Telangana, comprising a GMP-compliant injectable unit, a WHO-GMP injectable unit, a TGA-Australia and PIC/S accredited solid oral dosage unit, and a WHO-GMP cephalosporin facility. Its wholly owned subsidiary, Revat Laboratories, operates a GMP-certified facility in Ongole, Andhra Pradesh.
As of August 31, 2025, Sai Parenteral's Ltd. employed 277 full-time employees.
Strength Of Sai Parenteral's IPO
Risk Of Sai Parenteral's IPO
Objectives Sai Parenteral's IPO
1. Capacity expansion and upgradation of manufacturing facilities
2. Establishment of a new R&D Centre;
3. Repayment / prepayment of certain outstanding borrowings
4. Working capital requirements
5. Investment in wholly owned subsidiary, Sai Parenterals Pte Limited (Singapore), in relation to the proposed acquisition of Noumed Pharmaceuticals Pty Limited (Australia); and
6. General corporate purposes
Company Contact Details
Sai Parenteral's Ltd.
Plot No 39
5th floor, Lavanya Arcade Jayabheri Enclave
Gachibowli, K.V.Rangareddy, Seri Lingampally
Hyderabad, Telangana, 500032
Phone: +91 79979 91301
Email: cs@saiparenterals.com
Website: https://www.saiparenterals.com/
Registrar Contact Details
Lead Mangers
Lead Manager Reports
Sai Parenteral's IPO - FAQs
The Sai Parenteral's IPO is a MAINBOARD public issue comprising 0 equity shares with a face value of ₹5 each, aggregating to a total issue size of . The issue price has been fixed at ₹0 per equity share, and the minimum application size is 0 shares.
The IPO opens for subscription on TBA, and closes on TBA.
Bigshare Services Pvt Ltd has been appointed as the registrar to the issue. The equity shares are proposed to be listed on the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE).
As of now, the current GMP stands at TBA.